Enzymatic characteristics of CYP3A5 and CYP3A4:: A comparison of in vitro kinetic and drug-drug interaction patterns

被引:41
|
作者
Emoto, C. [1 ]
Iwasaki, K. [1 ]
机构
[1] Pfizer Japan Inc, Dept Pharmacokinet Dynam Metab, Nagoya Labs, Aichi 4702393, Japan
关键词
CYP3A4; CYP3A5; alpha-naphthoflavone; interaction;
D O I
10.1080/00498250500489968
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CYP3A4 and CYP3A5 exhibit significant overlap in substrate specificity, but can differ in catalytic activity and regioselectivity. To investigate their characteristics further, the enzymatic reactions of the two CYP3A enzymes were compared using midazolam, nifedipine, testosterone and terfenadine as substrates. Both CYP3A5 and CYP3A4 showed sigmoid and substrate inhibition patterns for testosterone 6 beta-hydroxylation and terfenadine t-butylhydroxylation (TFDOH), respectively. In the other reactions, the kinetic model for CYP3A5 was not similar to that for CYP3A4. An inhibition study demonstrated that the interactions between alpha-naphthoflavone (alpha NF) and CYP3A substrates were different for the two CYP3A enzymes. alpha NF stimulated nifedipine oxidation catalysed by CYP3A5, but did not stimulate that catalysed by CYP3A4. alpha NF at less than 32 mu M inhibited TFDOH catalysed by CYP3A5, but did not inhibit that catalysed by CYP3A4. These results indicate that CYP3A5 has different enzymatic characteristics from CYP3A4 in some CYP3A catalysed reactions.
引用
收藏
页码:219 / 233
页数:15
相关论文
共 50 条
  • [1] Comparison of CYP3A4 and CYP3A5 in Drug Metabolism and Drug Interactions
    Li, Shuanmei
    Liu, Duan
    Zhu, Juanli
    Cui, Yan
    Zhou, Ruimin
    Chen, Chao
    DRUG METABOLISM REVIEWS, 2009, 41 : 31 - 32
  • [2] Metabolic Pathway of Icotinib In Vitro: The Differential Roles of CYP3A4, CYP3A5, and CYP1A2 on Potential Pharmacokinetic Drug-Drug Interaction
    Zhang, TianHong
    Zhang, KeRong
    Ma, Li
    Li, Zheng
    Wang, Juan
    Zhang, YunXia
    Lu, Chuang
    Zhu, Mingshe
    Zhuang, XiaoMei
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 107 (04) : 979 - 983
  • [3] Comparative drug metabolism by CYP3A4 and CYP3A5
    Huang, WL
    Lin, YS
    Dai, Y
    Totah, RA
    Calamia, JC
    Thummel, KE
    DRUG METABOLISM REVIEWS, 2003, 35 : 187 - 187
  • [4] Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery
    Lolodi, Ogheneochukome
    Wang, Yue-Ming
    Wright, William C.
    Chen, Taosheng
    CURRENT DRUG METABOLISM, 2017, 18 (12) : 1095 - 1105
  • [5] A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro
    Fahmi, Odette A.
    Maurer, Tristan S.
    Kish, Mary
    Cardenas, Edwin
    Boldt, Sherri
    Nettleton, David
    DRUG METABOLISM AND DISPOSITION, 2008, 36 (08) : 1698 - 1708
  • [6] USE OF THE CYP3A4 SELECTIVE INHIBITOR CYP3CIDE IN CYP3A5 GENOTYPED CRYOPRESERVED HUMAN HEPATOCYTES TO EXPLORE THE INDIVIDUAL CONTRIBUTION OF CYP3A4 AND CYP3A5 IN DRUG METABOLISM
    Heyward, Scott
    Schultz, Rachel N. V.
    Dennell, Stephen
    DRUG METABOLISM REVIEWS, 2014, 45 : 135 - 136
  • [7] CYP3A4 HUMANIZED MOUSE; A MODEL TO STUDY CYP3A4-MEDIATED DRUG-DRUG INTERACTION POTENTIAL
    Rose, Anne
    Xu, Carrie
    Johnghar, Susan
    Behnia, Kamelia
    DRUG METABOLISM REVIEWS, 2012, 44 : 76 - 77
  • [8] CYP3A4 and CYP3A5 genotyping by pyrosequencing
    Garsa, AA
    McLeod, HL
    Marsh, S
    BMC MEDICAL GENETICS, 2005, 6
  • [9] In vitro interactions of abiraterone, erythromycin, and CYP3A4: implications for drug-drug interactions
    Masamrekh, Rami A.
    Kuzikov, Alexey V.
    Haurychenka, Yaraslau I.
    Shcherbakov, Kirill A.
    Veselovsky, Alexander V.
    Filimonov, Dmitrii A.
    Dmitriev, Alexander V.
    Zavialova, Maria G.
    Gilep, Andrei A.
    Shkel, Tatsiana V.
    Strushkevich, Natallia V.
    Usanov, Sergey A.
    Archakov, Alexander I.
    Shumyantseva, Victoria V.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2020, 34 (01) : 120 - 130
  • [10] Drug-drug interaction between tamsulosin and diltiazem, a moderate CYP3A4 inhibitor
    Byeon, Ji-Yeong
    Park, Jung-In
    Jang, Choon-Gon
    Lee, Seok-Yong
    PHARMACOTHERAPY, 2012, 32 (10): : E238 - E239